Supplemental New Drug Application Submitted to FDA by Janssen
Share
Follow Us
The Editors at Hepatitis Central
July 22, 2014
Find out about Janssen’s goal for Olysio to be used once-daily in combination with Sovaldi.
ISSUE: JULY 2014
Janssen Submits Supplemental NDA For Olysio for Once-Daily Use In Combination With Sofosbuvir
On May 7, Janssen announced the submission of a Supplemental New Drug Application (sNDA) to the FDA for simeprevir (Olysio), an NS3/4A hepatitis C virus (HCV) protease inhibitor, in combination with the NS5B HCV polymerase inhibitor, sofosbuvir (Sovaldi, Gilead Sciences). Janssen is seeking regulatory approval of the combination for the treatment of HCV genotype 1 infection in treatment-naive patients with advanced liver fibrosis and in null responders with all stages of liver fibrosis.
Continue reading this entire article:
http://www.idse.net/ViewArticle.aspx?d=Hepatitis&d_id=213&i=July+2014&i_id=1086&a_id=27752
3 Comments
I see its paying off for those of us on the trial having done so well. This is pills dor less than 90 days and they cost more than $1,000 a day. So yea us, we just made a ton of money for this drug company.
Michele – Did your insurance pay for the drug?
Wow, maybe by the time my insurance approves treatment this will be out. I Was set to start Solvaldi, rin, interferon, but doctor ordered another ultrsound. 3 this year so far. Well the Doctor who looked at the ultra said my pancreas needs a cat scan. Which my insurance will not cover. I swear i want to beat someone. I want control of my life again. I;m just about to say Screw you big pharm and go with cannabis oil all together,